New Drug for Duchenne Muscular Dystrophy Clears Phase 1 Clinical Trial Testing in Boys

Medication targets NF-κB, a key link between loss of dystrophin and disease progression, and may benefit all DMD patients regardless of genetic mutation, according to research published in JND

February 21, 2019 - Amsterdam, NL – Patients with Duchenne muscular dystrophy (DMD) have few treatment options. Medications currently available or in development either target only a subset of DMD patients with a particular genetic mutation or cause significant side effects. The investigational drug edasalonexent, an oral NF-κB inhibitor, has the potential to slow the progression of the disease for all patients with DMD. The results of a Phase I clinical trial published in the Journal of Neuromuscular Diseases indicate that the drug was well tolerated with no safety issues in boys with DMD, paving the way for further clinical testing. More...

February 21, 2019

Can We Repair the Brain? The Promise of Stem Cell Technologies for Treating Parkinson’s Disease

Despite challenges, new advances in stem cell biology and genetic engineering show potential for better cell replacement therapies, say experts in a special supplement to JPD

February 14, 2019 - Amsterdam, NL – Cell replacement may play an increasing role in alleviating the motor symptoms of Parkinson's disease (PD) in future. Writing in an open access special supplement to the Journal of Parkinson's Disease, experts describe how newly developed stem cell technologies could be used to treat the disease and discuss the great promise, as well as the significant challenges, of stem cell treatment. More...

February 14, 2019

No Association Between Antiepileptic Drug Use and Dementia Risk

Study investigates over 100,000 patients followed in general and neuropsychiatrist practices in Germany

February 13, 2019 - Frankfurt, Germany – Epilepsy is a common neurological condition with a prevalence of around 2%. Many antiepileptic drugs (AED) are available to prevent epileptic seizures, allowing up to 80 percent of patients to become seizure-free. However, previous research has found a positive association between the use of AEDs and dementia. More...

February 13, 2019

The Search for the Holy Grail: Promising Strategies for Slowing, Stopping, or Reversing Parkinson’s Disease

Experts review current research trends and evaluate which of these are likely to succeed over the next two decades, in a special supplement to JPD

February 12, 2019 - Amsterdam, NL – Understanding of the processes involved in Parkinson's disease (PD) degeneration has vastly improved over the last 20 years. In this insightful review published in an open access special supplement to the Journal of Parkinson's Disease, experts consider which of the existing strategies to slow down or stop the degenerative processes of PD are most likely to be successful over the next 20 years. More...

February 12, 2019